ecancer

New approaches and new partnership models for biomarker based clinical research

Dr Denis Lacombe, EORTC, Brussels, Belgium

6 Jan 2015

Aims and successes of the 2nd EurocanPlatform project translational research course

Christina von Gertten, Karolinska Institutet, Stockholm, Sweden

6 Jan 2015

Epigenome deregulation in cancer

Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France

6 Jan 2015

Immunotherapy of cancer: recent progress and future challenges

Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden

6 Jan 2015

Reasons to attend the EurocanPlatform translational research course 2015

Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany

6 Jan 2015

2nd EurocanPlatform translational research course is good for networking

Dr Diana Montezuma, Portuguese Oncology Institute of Porto, Portugal

6 Jan 2015

Biobanking biological materials and linkage to clinical information

Dr Peter Riegman, Erasmus Medical Center, Rotterdam, The Netherlands

6 Jan 2015

Paediatric drug development and the importance of collaboration

Dr Giuseppe Barone, The Institute of Cancer Research, London, UK

6 Jan 2015

The role of health economics in cancer outcomes research

Prof Bengt Jönsson, Stockholm School of Economics, Stockholm, Sweden

6 Jan 2015

Should young adults with acute lymphocytic leukaemia receive paediatric treatment protocols?

Dr Wendy Stock - University of Chicago, Chicago, USA

8 Dec 2014

Children with rare leukaemia have better-than-expected outcomes after tailored treatment

Dr Brent Wood - Seattle Children's Hospital, Seattle, USA

7 Dec 2014

Immunology highlights from ASH 2014

Dr Catherine Bollard - George Washington University, Washington, USA

7 Dec 2014

More from ecancer